Author

Zhen-Yu Li

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003).

BACKGROUND POM-MM-003 study compared pomalidomide-bortezomib-dexamethasone (PVd) with Vd in newly diagnosed multiple myeloma (NDMM) patients with RI. METHODS POM-MM-003 was open-label, randomized, phase II study done at eight centers in China (ClinicalTrials.gov: NCT05432414). Patients with symptomatic NDMM with RI (...

F. Xiao, Li-Ru Wang, Fei Li et al. · i Medicina · 1 citation

Open access Sep 2026

Construction and Validation of a Progression‐Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification

To investigate the clinical characteristics of newly diagnosed multiple myeloma (NDMM) patients with 1q21 gain/amplification (1q21+), construct and validate a progression‐free survival (PFS) prediction model, and explore the clinical implications of model‐based risk stratification.

Yue-Xuan Rao, Shi-You Li, Ao-Yang Yu et al. · Cancer Medicine · 0 citations